Community Health Centers Move to the COVID-19 Immunization Frontline

A new analysis from the Geiger Gibson/RCHN Community Health Foundation Research Collaborative provides current information on the number of community health center staff members and patients who have received COVID-19 vaccines, using data from the latest published Health Resources and Services Administration’s Health Center COVID-19 Survey. The Geiger Gibson/RCHN Community Health Foundation Research Collaborative is based at the George Washington University Milken Institute School of Public Health (GW Milken Institute SPH).

How to talk to patients of color about the COVID-19 vaccine amid hesitancy and mistrust

A new Annals of Internal Medicine editorial co-authored by a University of Chicago Medicine health disparities researcher offers practical tips for clinicians to discuss the COVID-19 vaccine with patients of color who may be hesitant to get vaccinated.

NCCN Shares New Guidance Principles for Vaccinating People with Cancer Against COVID-19

The National Comprehensive Cancer Network put out new guidance for COVID-19 vaccinations in people with cancer, based on available evidence plus consensus from top hematology and oncology experts with particular expertise in infectious diseases, vaccine development and delivery, and medical ethics.

Behavioral Strategies to Promote a National COVID-19 Vaccine Program

National efforts to develop a coronavirus disease 2019 (COVID-19) vaccine at “warp speed” will likely yield a safe and effective vaccine by early 2021. However, this important milestone is only the first step in an equally important challenge: getting a majority of the U.S. public vaccinated.

Top Sports Medicine Experts to Address COVID-19 and Athlete Care

Competitors at all levels have been impacted by COVID-19. Team physicians, athletic trainers and physical therapists now face unique challenges caring for athletes. Top sports medicine experts will address key issues surrounding competitive and recreational athlete care during COVID-19 at the 2020 Advanced Team Physician Course, a collaborative effort between ACSM, AMSSM and AOSSM.

Baylor Scott & White Health Enrolls First Patients in the World in Trial for Inhaled Remdesivir

Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.

Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19

As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.

Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.

Taming COVID-19 Requires Urgent Search for Both Vaccine and Treatment

While scientists around the world search for a coronavirus vaccine, an equivalent effort should be made to develop drugs that would mitigate the virus’s effects on patients, says Johns Hopkins Carey Business School Senior Lecturer Bonnie Robeson, who previously served as a principal investigator in drug discovery and development at the National Cancer Institute.

Massachusetts Eye and Ear and Massachusetts General Hospital Advancing Novel Experimental Gene-based COVID-19 Vaccine, AAVCOVID

Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham, today announced progress towards the testing and development of an experimental vaccine called AAVCOVID, a novel gene-based vaccine candidate against SARS-CoV2, the virus that causes COVID-19. The AAVCOVID Vaccine Program is a unique, gene-based vaccine strategy that uses adeno-associated viral (AAV) vector, a clinically established gene transfer technology leveraging the properties of a harmless viral carrier.